September 30, 2022 Release Highlights Copied

09/30/20222022 VBCRelease note

Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).

MIPS Quality Measures Dashboard

The MIPS Quality Measures Dashboard has been updated to reflect 2022 specification changes for MIPS #238 Use of High-Risk Medications in Older Adults. We will now display 3 rates for the measure, however, the rate that will be submitted during MIPS submission is Rate 1 below:

Measure Update Practice Impact
MIPS #238: Use of High-Risk Medications in Older Adults Denominator exclusions:

  • Patients in hospice care for any part of the measurement period and patients receiving palliative care during the measurement period.

Numerator

  • Rate 1: Patients with at least two orders of high-risk medications from the same drug class.
  • Rate 2: Patients with at least two orders of high-risk medications from the same drug class (i.e., antipsychotics and benzodiazepines).
  • Total rate (the sum of the two previous numerators, deduplicated).

Numerator exclusions:

  • For patients with two or more antipsychotic prescriptions ordered, the measure now excludes those with a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder on or between January 1 of the year before the measurement period and the Index Prescription Start Date (IPSD) for antipsychotics.
  • For patients with two or more benzodiazepine prescriptions ordered, the measure now excludes patients with a diagnosis of seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, or severe generalized anxiety disorder on or between January 1 of the year before the measurement period and the IPSD for benzodiazepines.
 This measure will now display 3 rates, where Rate 1 is associated with performance and will be scored for MIPS reporting purposes. Removing the patients receiving palliative care during the measurement period may cause a slight decrease in the denominator.

Status of Dashboard Updates for 2022

CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed and Practice Insights is currently working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2022 requirements. The measures listed below either have no 2022 update required or have been updated.

Measure Description

MIPS Quality Measures Dashboard
#047 Advance Care Plan

#104

 Combination Androgen Deprivation Therapy for Prostate
#110 Preventive Care and Screening: Influenza Immunization
#128 Body Mass Index (BMI) Screening and Follow-Up Plan
#130 Current Medications Documentation
#134 Depression Screening
#143 Pain Intensity Quantified
#144 Pain Care Plan
#226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

#236

 Controlling High Blood Pressure
#374 Closing the Referral Loop
#451 RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
#453 Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure)

#457

Patients Admitted to Hospice for < 3 Days
PIMSH#1 Advance Care Planning in Metastatic Cancer
PIMSH#2 Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)
PIMSH#4 Patient-Reported Pain Improvement

PIMSH#8

 Mutation Testing for Lung Cancer
PIMSH#9 Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10 Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs

PIMSH#12

COVID-19 Vaccinations

OCM Performance Measures Dashboard 1H 2022
OCM 4A Pain Intensity Quantified
OCM 4B Plan of Care for Pain
OCM5 Depression Screening